PubMed Health⌕ Search

Biomedical subjects

F Loskot

Publications and source records attributed to F Loskot.

9 recordsLinked to original sources
PubMed1990

[Asymptomatic myocardial ischemia].

Silent (asymptomatic) myocardial ischemia (SMI) is defined as a transient alteration in myocardial perfusion in the absence of chest pain or the usual anginal equivalents. Patients may be classified as having one of the three types of SMI: type A--totally asymptomatic patients with no history of angina or myocardial infarction; type B--asymptomatic patients with previous myocardial infarction; type C--patients with angina and asymptomatic ischemic episodes. SMI has been found in 2.5% of all healthy males aged 40-59 and in 20% of all postinfarction patients. In type C-patients, 80% has been found to have asymptomatic ischemic episodes in addition to typical angina pectoris. The frequency of SMI may be up to three or four times that of anginal attacks. SMI patients have generally reduced sensitivity to pain an differences in severity an duration of ischemic episodes. Diagnosis is based on screening by means of exercise testing in patients working in specific professions (like pilots, busdrivers etc.), in postinfarction patients and in patients after unstable angina pectoris and after coronary bypass surgery or coronary angioplasty. Prognosis is the same as in asymptomatic ischemia. SMI is an indicator of instability in certain groups of patients (post infarction, after unstable angina pectoris). SMI persisting after medical therapy of unstable angina is associated with adverse short-term-prognosis, therefore coronary surgery or angioplasty is indicated.

Adult↗
PubMed1989

[Therapeutic coronary effectiveness of retard gallopamil following repeated administration in comparison with placebo].

The aim of this randomized double-blind crossover trial was to evaluate the therapeutic efficacy of 100 mg slow-release gallopamil compared to placebo. The results of multistage exercise tests with computer-assisted ECG were analyzed in 16 patients (14 men and two women) aged 39 to 66 years who fulfilled the angiographical evidence of coronary heart disease with stable angina pectoris. All cardioactive medication was withdrawn for the duration of the study except for the trial medication and sublingual nitroglycerin as required. Patients began the therapy with a 5-day placebo run-in period. After this regimen, they were randomized to placebo or slow-release gallopamil (200 mg/day) in two divided doses for 7 days, at the end of which time each patient crossed over to the alternate regimen. Exercise testing was repeated at the end of the run-in period and after 1 week of placebo or active drug therapy. At highest comparable load the ST-segment depression was reduced about 70% before the morning administration (i.e., 12 h after the evening administration) and 6 h after the morning administration. The work load (W x min) increased in 54% or 61% at the maximal possible load. The number of angina pectoris attacks under bicycle ergometer exercise decreased in about 50%. PR-interval was prolonged from 0.14 to 0.15 s. QRS- and OTc-intervals were not influenced. No clinically relevant changes in heart rate and blood pressure were observed. The results indicate great antianginal efficacy and a good toleration of slow-released gallopamil.

Administration, Oral↗
PubMed1988

Aortic arch replacement by posterolateral exposure.

Aortic arch replacement was carried out in a 54 year old male patient with an unexpected type A-dissection, using partial femoro-femoral bypass and hypothermic arrest, through a left side posterolateral thoracotomy. After the replacement of the aortic arch from the ascending to the descending aorta a warm-up perfusion was done through an 8 mm side arm Dacron prosthesis attached to the descending segment of the 30 mm Dacron graft. This technique was demonstrated to be safe and protective in our patient and can be used as an alternative surgical method in the treatment of aortic arch dissection or aneurysms of the transverse aortic arch.

Aortic Dissection↗
PubMed1987

PTFE grafts to the right coronary artery following endarterectomy.

In ten of 3031 patients undergoing coronary surgery, we used a PTFE graft for bypass to the right coronary artery following endarterectomy. Diffuse calcification was the reason for endarterectomy of the right coronary artery in all cases. We chose a PTFE graft only in those cases where autologous grafts were not available in a sufficient number. After a mean follow-up period of twelve months nine of the ten grafts were patent.--This study demonstrates that under selected circumstances PTFE grafts can be successfully used in coronary surgery if autologous grafts are lacking.

Blood Vessel Prosthesis↗
PubMedDate not supplied

The use of expanded polytetrafluoroethylene (PTFE) grafts for myocardial revascularization.

In 18 patients necessitating aorto-coronary bypass grafting procedures in whom suitable veins were not available, 22 PTFE grafts were used in combination with 47 saphenous-vein grafts. 14 patients were studied angiographically 1-26 months after operation, with a mean follow-up of 12 months. 59% of the expanded PTFE grafts and 86% saphenous vein grafts were patent. Factors affecting PTFE graft patency were similar to those of vein grafts. We conclude, that it is reasonable to use this artificial prosthesis only when sufficient veins are not available. Expanded PTFE grafts of 3-5 mm diameter can remain patent and functional for more than 2 years.

Blood Vessel Prosthesis↗